Mark J Walker

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1159983/publications.pdf

Version: 2024-02-01

198 papers	15,406 citations	31976 53 h-index	20358 116 g-index
204 all docs	204 docs citations	204 times ranked	22978 citing authors

#	Article	IF	Citations
1	Dysregulation of Streptococcus pneumoniae zinc homeostasis breaks ampicillin resistance in a pneumonia infection model. Cell Reports, 2022, 38, 110202.	6.4	18
2	Rescuing Tetracycline Class Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii Pulmonary Infection. MBio, 2022, 13, e0351721.	4.1	11
3	Neurodegenerative Disease Treatment Drug PBT2 Breaks Intrinsic Polymyxin Resistance in Gram-Positive Bacteria. Antibiotics, 2022, 11, 449.	3.7	3
4	An ionophore breaks the multi-drug-resistance of Acinetobacter baumannii. Microbial Cell, 2022, 9, 69-71.	3.2	1
5	Streptococcus pyogenes Hijacks Host Glutathione for Growth and Innate Immune Evasion. MBio, 2022, 13, e0067622.	4.1	15
6	A multivalent T-antigen-based vaccine for Group A Streptococcus. Scientific Reports, 2021, 11, 4353.	3.3	20
7	A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study. Lancet Microbe, The, 2021, 2, e291-e299.	7.3	29
8	Inflammasome activation and <scp>IL</scp> â€•1Î² signalling in group A <i>Streptococcus</i> disease. Cellular Microbiology, 2021, 23, e13373.	2.1	11
9	A drug candidate for Alzheimerâ€™s and Huntingtonâ€™s disease, PBT2, can be repurposed to render <i>Neisseria gonorrhoeae</i> susceptible to natural cationic antimicrobial peptides. Journal of Antimicrobial Chemotherapy, 2021, 76, 2850-2853.	3.0	4
10	Streptolysins are the primary inflammasome activators in macrophages during <i>Streptococcus pyogenes</i> infection. Immunology and Cell Biology, 2021, 99, 1040-1052.	2.3	12
11	The antimicrobial and immunomodulatory effects of Ionophores for the treatment of human infection. Journal of Inorganic Biochemistry, 2021, 227, 111661.	3.5	8
12	Streptococcal superantigens and the return of scarlet fever. PLoS Pathogens, 2021, 17, e1010097.	4.7	12
13	<i>Neisseria gonorrhoeae</i> Becomes Susceptible to Polymyxin B and Colistin in the Presence of PBT2. ACS Infectious Diseases, 2020, 6, 50-55.	3.8	21
14	Semisynthetic, self-adjuvanting vaccine development: Efficient, site-specific sortase A-mediated conjugation of Toll-like receptor 2 ligand FSL-1 to recombinant protein antigens under native conditions and application to a model group A streptococcal vaccine. Journal of Controlled Release, 2020, 317, 96-108.	9.9	21
15	Prophage exotoxins enhance colonization fitness in epidemic scarlet fever-causing Streptococcus pyogenes. Nature Communications, 2020, 11, 5018.	12.8	35
16	Repurposing a neurodegenerative disease drug to treat Gram-negative antibiotic-resistant bacterial sepsis. Science Translational Medicine, 2020, 12, .	12.4	36
17	Role of Glutathione in Buffering Excess Intracellular Copper in <i>Streptococcus pyogenes</i>. MBio, 2020, 11, .	4.1	40
18	Analysis of Global Collection of Group A <i>Streptococcus</i> Genomes Reveals that the Majority Encode a Trio of M and M-Like Proteins. MSphere, 2020, 5, .	2.9	16

#	Article	IF	Citations
19	Vaccine-Induced Th1-Type Response Protects against Invasive Group A <i>Streptococcus</i> Infection in the Absence of Opsonizing Antibodies. MBio, 2020, 11, .	4.1	33
20	Antimicrobial Resistance in ESKAPE Pathogens. Clinical Microbiology Reviews, 2020, 33, .	13.6	898
21	Update on group A streptococcal vaccine development. Current Opinion in Infectious Diseases, 2020, 33, 244-250.	3.1	56
22	All major cholesterol-dependent cytolysins use glycans as cellular receptors. Science Advances, 2020, 6, eaaz4926.	10.3	46
23	Multiple Bactericidal Mechanisms of the Zinc Ionophore PBT2. MSphere, 2020, 5, .	2.9	24
24	Humanized Plasminogen Mouse Model to Study Group A Streptococcus Invasive Disease. Methods in Molecular Biology, 2020, 2136, 309-316.	0.9	5
25	Genetic Manipulation of Group A Streptococcusâ€"Gene Deletion by Allelic Replacement. Methods in Molecular Biology, 2020, 2136, 59-69.	0.9	8
26	Investigation of Group A Streptococcal Interactions with Host Glycan Structures Using High-Throughput Techniques: Glycan Microarray Analysis Using Recombinant Protein and Whole Cells. Methods in Molecular Biology, 2020, 2136, 145-151.	0.9	1
27	Human glycan expression patterns influence Group A streptococcal colonization of epithelial cells. FASEB Journal, 2019, 33, 10808-10818.	0.5	5
28	The Serotype-Specific Role of Regulator of Cov Polymorphisms in the Pathogenesis of Invasive Group A Streptococcal Infections. American Journal of Pathology, 2019, 189, 1913-1915.	3.8	1
29	Scarlet fever changes its spots. Lancet Infectious Diseases, The, 2019, 19, 1154-1155.	9.1	8
30	Group A <i>Streptococcus</i> co-ordinates manganese import and iron efflux in response to hydrogen peroxide stress. Biochemical Journal, 2019, 476, 595-611.	3.7	20
31	Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics. Nature Genetics, 2019, 51, 1035-1043.	21.4	120
32	Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study. Vaccine, 2019, 37, 3485-3494.	3.8	31
33	Characterizing the role of tissue-type plasminogen activator in a mouse model of Group A streptococcal infection. Microbes and Infection, 2019, 21, 412-417.	1.9	2
34	An Experimental Group A <i>Streptococcus</i> Vaccine That Reduces Pharyngitis and Tonsillitis in a Nonhuman Primate Model. MBio, 2019, 10, .	4.1	57
35	Discovery of glycerol phosphate modification on streptococcal rhamnose polysaccharides. Nature Chemical Biology, 2019, 15, 463-471.	8.0	53
36	Detection of Epidemic Scarlet Fever Group A Streptococcus in Australia. Clinical Infectious Diseases, 2019, 69, 1232-1234.	5.8	19

#	Article	IF	Citations
37	A Controlled Human Infection Model of Group A <i>Streptococcus</i> Pharyngitis: Which Strain and Why?. MSphere, 2019, 4, .	2.9	24
38	Increased Incidence of Scarlet Fever - China, 1999-2018. China CDC Weekly, 2019, 1, 63-66.	2.3	0
39	Group A streptococcal pharyngitis: Immune responses involved in bacterial clearance and GAS-associated immunopathologies. Journal of Leukocyte Biology, 2018, 103, 193-213.	3.3	43
40	Endopeptidase PepO Regulates the SpeB Cysteine Protease and Is Essential for the Virulence of Invasive M1T1 Streptococcus pyogenes. Journal of Bacteriology, 2018, 200, .	2.2	18
41	Group A streptococcal M-like proteins: From pathogenesis to vaccine potential. FEMS Microbiology Reviews, 2018, 42, 193-204.	8.6	34
42	Scarlet Fever Epidemic in China Caused by Streptococcus pyogenes Serotype M12: Epidemiologic and Molecular Analysis. EBioMedicine, 2018, 28, 128-135.	6.1	67
43	New Insights into the Role of Zinc Acquisition and Zinc Tolerance in Group A Streptococcal Infection. Infection and Immunity, 2018, 86, .	2.2	41
44	Scarlet fever makes a comeback. Lancet Infectious Diseases, The, 2018, 18, 128-129.	9.1	13
45	Virulence Role of the GlcNAc Side Chain of the Lancefield Cell Wall Carbohydrate Antigen in Non-M1-Serotype Group A<i>Streptococcus</i>. MBio, 2018, 9, .	4.1	30
46	Chemical Synergy between Ionophore PBT2 and Zinc Reverses Antibiotic Resistance. MBio, 2018, 9, .	4.1	56
47	Lipoteichoic acid anchor triggers Mincle to drive protective immunity against invasive group A<i>Streptococcus</i>infection. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10662-E10671.	7.1	37
48	A Host Proteome Atlas of Streptococcus pyogenes Infection. Cell Systems, 2018, 6, 536-538.	6.2	0
49	Group A Streptococcus M1T1 Intracellular Infection of Primary Tonsil Epithelial Cells Dampens Levels of Secreted IL-8 Through the Action of SpyCEP. Frontiers in Cellular and Infection Microbiology, 2018, 8, 160.	3.9	23
50	Complete Genome Sequence of a Streptococcus pyogenes Serotype M12 Scarlet Fever Outbreak Isolate from China, Compiled Using Oxford Nanopore and Illumina Sequencing. Genome Announcements, 2018, 6, .	0.8	3
51	Hypotheses for the resurgence of scarlet fever in China. Lancet Infectious Diseases, The, 2018, 18, 942-943.	9.1	1
52	Microevolution of Streptococcus agalactiae ST-261 from Australia Indicates Dissemination via Imported Tilapia and Ongoing Adaptation to Marine Hosts or Environment. Applied and Environmental Microbiology, 2018, 84, .	3.1	33
53	Blood Group Antigen Recognition via the Group A Streptococcal M Protein Mediates Host Colonization. MBio, 2017, 8, .	4.1	25
54	Transition Metal Homeostasis in Streptococcus pyogenes and Streptococcus pneumoniae. Advances in Microbial Physiology, 2017, 70, 123-191.	2.4	32

#	Article	IF	Citations
55	The PerR-Regulated P _{1B-4} -Type ATPase (PmtA) Acts as a Ferrous Iron Efflux Pump in Streptococcus pyogenes. Infection and Immunity, 2017, 85, .	2.2	24
56	Interplay between tolerance mechanisms to copper and acid stress in <i>Escherichia coli</i>. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 6818-6823.	7.1	57
57	Linoleic and palmitoleic acid block streptokinase-mediated plasminogen activation and reduce severity of invasive group A streptococcal infection. Scientific Reports, 2017, 7, 11798.	3.3	4
58	Caveolin 1 restricts Group AStreptococcusinvasion of nonphagocytic host cells. Cellular Microbiology, 2017, 19, e12772.	2.1	11
59	Modifications in the pmrB gene are the primary mechanism for the development of chromosomally encoded resistance to polymyxins in uropathogenic Escherichia coli. Journal of Antimicrobial Chemotherapy, 2017, 72, 2729-2736.	3.0	41
60	Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models. MBio, 2016, 7, .	4.1	51
61	<i>Streptococcus pyogenes</i> adhesion and colonization. FEBS Letters, 2016, 590, 3739-3757.	2.8	96
62	Interleukin-17A Contributes to the Control of Streptococcus pyogenes Colonization and Inflammation of the Female Genital Tract. Scientific Reports, 2016, 6, 26836.	3.3	25
63	Tribute to professor Gursharan Singh Chhatwal. Environmental Microbiology Reports, 2016, 8, 553-553.	2.4	0
64	Streptococcus iniae cpsG alters capsular carbohydrate composition and is a cause of serotype switching in vaccinated fish. Veterinary Microbiology, 2016, 193, 116-124.	1.9	7
65	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
66	Defence against methylglyoxal in Group A<i>Streptococcus</i>: a role for Glyoxylase I in bacterial virulence and survival in neutrophils?. Pathogens and Disease, 2016, 74, ftv122.	2.0	20
67	<i>Salmonella</i> employs multiple mechanisms to subvert the TLRâ€inducible zincâ€mediated antimicrobial response of human macrophages. FASEB Journal, 2016, 30, 1901-1912.	0.5	91
68	Hospital-wide Eradication of a Nosocomial<i>Legionella pneumophila</i>Serogroup 1 Outbreak. Clinical Infectious Diseases, 2016, 62, 273-279.	5.8	49
69	Streptococcal toxins: role in pathogenesis and disease. Cellular Microbiology, 2015, 17, 1721-1741.	2.1	76
70	Transfer of scarlet fever-associated elements into the group A Streptococcus M1T1 clone. Scientific Reports, 2015, 5, 15877.	3.3	57
71	Stability of the Octameric Structure Affects Plasminogen-Binding Capacity of Streptococcal Enolase. PLoS ONE, 2015, 10, e0121764.	2.5	14
72	Zinc disrupts central carbon metabolism and capsule biosynthesis in Streptococcus pyogenes. Scientific Reports, 2015, 5, 10799.	3.3	100

#	Article	IF	Citations
73	Hostâ€“pathogen interaction during bacterial vaccination. Current Opinion in Immunology, 2015, 36, 1-7.	5.5	21
74	Group A <i>Streptococcus</i> Modulates Host Inflammation by Manipulating Polymorphonuclear Leukocyte Cell Death Responses. Journal of Innate Immunity, 2015, 7, 612-622.	3.8	9
75	Manganese Homeostasis in Group A Streptococcus Is Critical for Resistance to Oxidative Stress and Virulence. MBio, 2015, 6, .	4.1	62
76	The Role of Copper and Zinc Toxicity in Innate Immune Defense against Bacterial Pathogens. Journal of Biological Chemistry, 2015, 290, 18954-18961.	3.4	324
77	Molecular typing of Chinese Streptococcus pyogenes isolates. Molecular and Cellular Probes, 2015, 29, 172-176.	2.1	2
78	Emergence of scarlet fever Streptococcus pyogenes emm12 clones in Hong Kong is associated with toxin acquisition and multidrug resistance. Nature Genetics, 2015, 47, 84-87.	21.4	135
79	Mutual Exclusivity of Hyaluronan and Hyaluronidase in Invasive Group A Streptococcus. Journal of Biological Chemistry, 2014, 289, 32303-32315.	3.4	30
80	An Antimicrobial Role for Zinc in Innate Immune Defense Against Group A Streptococcus. Journal of Infectious Diseases, 2014, 209, 1500-1508.	4.0	123
81	Site-restricted plasminogen activation mediated by group A streptococcal streptokinase variants. Biochemical Journal, 2014, 458, 23-31.	3.7	14
82	Host Responses to Group A Streptococcus: Cell Death and Inflammation. PLoS Pathogens, 2014, 10, e1004266.	4.7	40
83	Plasmin(ogen) Acquisition by Group A <i>Streptococcus</i> Protects against C3b-Mediated Neutrophil Killing. Journal of Innate Immunity, 2014, 6, 240-250.	3.8	34
84	The cholesterol-dependent cytolysins pneumolysin and streptolysin O require binding to red blood cell glycans for hemolytic activity. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5312-20.	7.1	110
85	Tracking antibiotic resistance. Science, 2014, 345, 1454-1455.	12.6	35
86	Disease Manifestations and Pathogenic Mechanisms of Group A Streptococcus. Clinical Microbiology Reviews, 2014, 27, 264-301.	13.6	668
87	A Systematic and Functional Classification of Streptococcus pyogenes That Serves as a New Tool for Molecular Typing and Vaccine Development. Journal of Infectious Diseases, 2014, 210, 1325-1338.	4.0	257
88	Streptococcus agalactiae clones infecting humans were selected and fixed through the extensive use of tetracycline. Nature Communications, 2014, 5, 4544.	12.8	208
89	Evaluation of recombinant Mycoplasma hyopneumoniae P97/P102 paralogs formulated with selected adjuvants as vaccines against mycoplasmal pneumonia in pigs. Vaccine, 2014, 32, 4333-4341.	3.8	25
90	Working towards a Group A Streptococcal vaccine: Report of a collaborative Trans-Tasman workshop. Vaccine, 2014, 32, 3713-3720.	3.8	44

#	Article	IF	Citations
91	The Classical Lancefield Antigen of Group A Streptococcus Is a Virulence Determinant with Implications for Vaccine Design. Cell Host and Microbe, 2014, 15, 729-740.	11.0	121
92	The contribution of non-human primate models to the development of human vaccines. Discovery Medicine, 2014, 18, 313-22.	0.5	26
93	The Globally Disseminated M1T1 Clone of Group A Streptococcus Evades Autophagy for Intracellular Replication. Cell Host and Microbe, 2013, 14, 675-682.	11.0	134
94	Streptococcal collagenâ€like protein A and general stress protein 24 are immunomodulating virulence factors of group A Streptococcus. FASEB Journal, 2013, 27, 2633-2643.	0.5	18
95	A Key Role for the Urokinase Plasminogen Activator (uPA) in Invasive Group A Streptococcal Infection. PLoS Pathogens, 2013, 9, e1003469.	4.7	17
96	Molecular Characterization of Endocarditis-Associated Staphylococcus aureus. Journal of Clinical Microbiology, 2013, 51, 2131-2138.	3.9	30
97	Interplay between Manganese and Iron in Pneumococcal Pathogenesis: Role of the Orphan Response Regulator RitR. Infection and Immunity, 2013, 81, 421-429.	2.2	35
98	Structure-Informed Design of an Enzymatically Inactive Vaccine Component for Group A <i>Streptococcus</i>. MBio, 2013, 4, .	4.1	18
99	Acquisition of the Sda1-Encoding Bacteriophage Does Not Enhance Virulence of the Serotype M1 Streptococcus pyogenes Strain SF370. Infection and Immunity, 2013, 81, 2062-2069.	2.2	19
100	Extensive Diversity of Streptococcus pyogenes in a Remote Human Population Reflects Global-Scale Transmission Rather than Localised Diversification. PLoS ONE, 2013, 8, e73851.	2.5	21
101	Sequences of Two Related Multiple Antibiotic Resistance Virulence Plasmids Sharing a Unique IS26-Related Molecular Signature Isolated from Different Escherichia coli Pathotypes from Different Hosts. PLoS ONE, 2013, 8, e78862.	2.5	80
102	Outsmarting Outbreaks. Science, 2012, 338, 1161-1162.	12.6	13
103	Group A Streptococcal Vaccine Candidates: Potential for the Development of a Human Vaccine. Current Topics in Microbiology and Immunology, 2012, 368, 207-242.	1.1	29
104	Molecular Characterization of the 2011 Hong Kong Scarlet Fever Outbreak. Journal of Infectious Diseases, 2012, 206, 341-351.	4.0	89
105	Characterization of Cleavage Events in the Multifunctional Cilium Adhesin Mhp684 (P146) Reveals a Mechanism by Which Mycoplasma hyopneumoniae Regulates Surface Topography. MBio, 2012, 3, .	4.1	54
106	The Role of Streptokinase as a Virulence Determinant of Streptococcus pyogenes â€" Potential for Therapeutic Targeting. Current Drug Targets, 2012, 13, 297-307.	2.1	28
107	Evaluation of clinical, histological and immunological changes and qPCR detection of Mycoplasma hyopneumoniae in tissues during the early stages of mycoplasmal pneumonia in pigs after experimental challenge with two field isolates. Veterinary Microbiology, 2012, 161, 186-195.	1.9	47
108	<i>Mycoplasma hyopneumoniae</i> Surface Proteins Mhp385 and Mhp384 Bind Host Cilia and Glycosaminoglycans and Are Endoproteolytically Processed by Proteases That Recognize Different Cleavage Motifs. Journal of Proteome Research, 2012, 11, 1924-1936.	3.7	52

#	ARTICLE	IF	CITATIONS
109	Analysis of a Streptococcus pyogenes Puerperal Sepsis Cluster by Use of Whole-Genome Sequencing. Journal of Clinical Microbiology, 2012, 50, 2224-2228.	3.9	55
110	Tracing the evolutionary history of the pandemic group A streptococcal M1T1 clone. FASEB Journal, 2012, 26, 4675-4684.	0.5	48
111	Streptokinase variants from <i><scp>S</scp>treptococcus pyogenes</i> isolates display altered plasminogen activation characteristics â€" implications for pathogenesis. Molecular Microbiology, 2012, 86, 1052-1062.	2.5	34
112	Editorial: [Hot Topic: Establishment of the Australian Infectious Diseases Research Centre]. Current Drug Targets, 2012, 13, 1347-1347.	2.1	0
113	Conserved anchorless surface proteins as group A streptococcal vaccine candidates. Journal of Molecular Medicine, 2012, 90, 1197-1207.	3.9	49
114	Mhp182 (P102) binds fibronectin and contributes to the recruitment of plasmin(ogen) to the Mycoplasma hyopneumoniae cell surface. Cellular Microbiology, 2012, 14, 81-94.	2.1	76
115	Polyelectrolyte Complex Materials Consisting of Antibacterial and Cellâ€Supporting Layers. Macromolecular Bioscience, 2012, 12, 374-382.	4.1	25
116	Molecular Characterization of a 21.4 Kilobase Antibiotic Resistance Plasmid from an Î±-Hemolytic Escherichia coli O108:H- Human Clinical Isolate. PLoS ONE, 2012, 7, e34718.	2.5	0
117	Pathogenesis of group A streptococcal infections. Discovery Medicine, 2012, 13, 329-42.	0.5	47
118	Molecular insight into invasive group A streptococcal disease. Nature Reviews Microbiology, 2011, 9, 724-736.	28.6	337
119	Mhp107 Is a Member of the Multifunctional Adhesin Family of Mycoplasma hyopneumoniae. Journal of Biological Chemistry, 2011, 286, 10097-10104.	3.4	46
120	Sequence TTKFâ†"QE Defines the Site of Proteolytic Cleavage in Mhp683 Protein, a Novel Glycosaminoglycan and Cilium Adhesin of Mycoplasma hyopneumoniae. Journal of Biological Chemistry, 2011, 286, 41217-41229.	3.4	47
121	Effects on human plasminogen conformation and activation rate caused by interaction with VEK-30, a peptide derived from the group A streptococcal M-like protein (PAM). Biochimica Et Biophysica Acta - Proteins and Proteomics, 2010, 1804, 1342-1349.	2.3	5
122	Integrating neighbor clustering, coexpression clustering and subsystems analysis to define dynamic changes in regulatory networks associated with group A streptococcal sociomicrobiology and niche adaptation. BMC Bioinformatics, 2010, 11, .	2.6	0
123	Repeat regions R1 and R2 in the P97 paralogue Mhp271 of <i>Mycoplasma hyopneumoniae</i> bind heparin, fibronectin and porcine cilia. Molecular Microbiology, 2010, 78, 444-458.	2.5	74
124	Distribution of Class 1 Integrons with IS26-Mediated Deletions in Their 3â€²-Conserved Segments in Escherichia coli of Human and Animal Origin. PLoS ONE, 2010, 5, e12754.	2.5	108
125	Multiple antibiotic resistance gene recruitment onto the enterohemorrhagic <i>Escherichia coli</i> virulence plasmid. FASEB Journal, 2010, 24, 1160-1166.	0.5	85
126	A Processed Multidomain Mycoplasma hyopneumoniae Adhesin Binds Fibronectin, Plasminogen, and Swine Respiratory Cilia. Journal of Biological Chemistry, 2010, 285, 33971-33978.	3.4	77

#	Article	IF	Citations
127	Genetic Switch to Hypervirulence Reduces Colonization Phenotypes of the Globally Disseminated Group A<i>Streptococcus</i>M1T1 Clone. Journal of Infectious Diseases, 2010, 202, 11-19.	4.0	95
128	Parameters Governing Invasive Disease Propensity of Non-M1 Serotype Group A Streptococci. Journal of Innate Immunity, 2010, 2, 596-606.	3.8	36
129	M Protein and Hyaluronic Acid Capsule Are Essential for <i>In Vivo</i> Selection of <i>covRS</i> Mutations Characteristic of Invasive Serotype M1T1 Group A <i>Streptococcus</i>. MBio, 2010, 1, .	4.1	116
130	A quantitative NMR spectroscopic examination of the flexibility of the C-terminal extensions of the molecular chaperones, Î±A- and Î±B-crystallin. Experimental Eye Research, 2010, 91, 691-699.	2.6	56
131	Microevolution of Group A Streptococci In Vivo: Capturing Regulatory Networks Engaged in Sociomicrobiology, Niche Adaptation, and Hypervirulence. PLoS ONE, 2010, 5, e9798.	2.5	43
132	Development of Non-Antibiotic-Resistant, Chromosomally Based, Constitutive and Inducible Expression Systems for <i>aroA</i> -Attenuated <i>Salmonella enterica</i> Serovar Typhimurium. Infection and Immunity, 2009, 77, 1817-1826.	2.2	19
133	Defining the Structural Basis of Human Plasminogen Binding by Streptococcal Surface Enolase. Journal of Biological Chemistry, 2009, 284, 17129-17137.	3.4	61
134	Mhp493 (P216) is a proteolytically processed, cilium and heparin binding protein of<i>Mycoplasma hyopneumoniae</i>. Molecular Microbiology, 2009, 71, 566-582.	2.5	62
135	Human pathogenic streptococcal proteomics and vaccine development. Proteomics - Clinical Applications, 2008, 2, 387-410.	1.6	38
136	Glutamic acid residues in the Câ€terminal extension of small heat shock proteinâ€ƒ25 are critical for structural and functional integrity. FEBS Journal, 2008, 275, 5885-5898.	4.7	27
137	Isolation and Solubilization of Gram-Positive Bacterial Cell Wall-Associated Proteins. Methods in Molecular Biology, 2008, 425, 295-311.	0.9	18
138	Opacity Factor Activity and Epithelial Cell Binding by the Serum Opacity Factor Protein of Streptococcus pyogenes Are Functionally Discrete. Journal of Biological Chemistry, 2008, 283, 6359-6366.	3.4	25
139	M proteinâ€mediated plasminogen binding is essential for the virulence of an invasive<i>Streptococcus pyogenes</i>isolate. FASEB Journal, 2008, 22, 2715-2722.	0.5	72
140	Allelic variants of streptokinase from<i>Streptococcus pyogenes</i>display functional differences in plasminogen activation. FASEB Journal, 2008, 22, 3146-3153.	0.5	55
141	A Naturally Occurring Mutation in ropB Suppresses SpeB Expression and Reduces M1T1 Group A Streptococcal Systemic Virulence. PLoS ONE, 2008, 3, e4102.	2.5	60
142	The Plasminogen-Binding Group A Streptococcal M Protein-Related Protein Prp Binds Plasminogen via Arginine and Histidine Residues. Journal of Bacteriology, 2007, 189, 1435-1440.	2.2	71
143	Comparative Analysis of Virulence Genes, Genetic Diversity, and Phylogeny of Commensal and Enterotoxigenic Escherichia coli Isolates from Weaned Pigs. Applied and Environmental Microbiology, 2007, 73, 83-91.	3.1	51
144	New understanding of the group A Streptococcus pathogenesis cycle. Trends in Microbiology, 2007, 15, 318-325.	7.7	103

#	Article	IF	Citations
145	Role of group A <i>Streptococcus</i> HtrA in the maturation of SpeB protease. Proteomics, 2007, 7, 4488-4498.	2.2	42
146	DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nature Medicine, 2007, 13, 981-985.	30.7	371
147	Characterization of mesophilic bacilli in faeces of feedlot cattle. Journal of Applied Microbiology, 2007, 102, 872-879.	3.1	21
148	Site-Directed Mutations in the C-Terminal Extension of Human Î±B-Crystallin Affect Chaperone Function and Block Amyloid Fibril Formation. PLoS ONE, 2007, 2, e1046.	2.5	44
149	Inhibition of indoleamine 2,3 dioxygenase activity by H2O2. Archives of Biochemistry and Biophysics, 2006, 450, 9-19.	3.0	30
150	Development of a group-specific PCR combined with ARDRA for the identification of Bacillus species of environmental significance. Journal of Microbiological Methods, 2006, 64, 107-119.	1.6	78
151	Non-motile mini-transposon mutants of Bordetella bronchiseptica exhibit altered abilities to invade and survive in eukaryotic cells. FEMS Microbiology Letters, 2006, 146, 263-269.	1.8	13
152	Domains of group A streptococcal M protein that confer resistance to phagocytosis, opsonization and protection: implications for vaccine development. Molecular Microbiology, 2006, 59, 1-4.	2.5	38
153	P159 is a proteolytically processed, surface adhesin of Mycoplasma hyopneumoniae: defined domains of P159 bind heparin and promote adherence to eukaryote cells. Molecular Microbiology, 2006, 60, 669-686.	2.5	89
154	Serum opacity factor promotes group A streptococcal epithelial cell invasion and virulence. Molecular Microbiology, 2006, 62, 15-25.	2.5	46
155	Two Domains within the Mycoplasma hyopneumoniae Cilium Adhesin Bind Heparin. Infection and Immunity, 2006, 74, 481-487.	2.2	56
156	Trigger for group A streptococcal M1T1 invasive disease. FASEB Journal, 2006, 20, 1745-1747.	0.5	140
157	Divergence in the Plasminogen-binding Group A Streptococcal M Protein Family. Journal of Biological Chemistry, 2006, 281, 3217-3226.	3.4	32
158	The Maintenance of High Affinity Plasminogen Binding by Group A Streptococcal Plasminogen-binding M-like Protein Is Mediated by Arginine and Histidine Residues within the a1 and a2 Repeat Domains. Journal of Biological Chemistry, 2006, 281, 25965-25971.	3.4	43
159	R120G Î±B-crystallin promotes the unfolding of reduced Î±-lactalbumin and is inherently unstable. FEBS Journal, 2005, 272, 711-724.	4.7	78
160	Surface Analyses and Immune Reactivities of Major Cell Wall-Associated Proteins of Group A Streptococcus. Infection and Immunity, 2005, 73, 3137-3146.	2.2	99
161	Is plasminogen deployed as a Streptococcus pyogenes virulence factor?. Trends in Microbiology, 2005, 13, 308-313.	7.7	95
162	Plasminogen Binding by Group A Streptococcal Isolates from a Region of Hyperendemicity for Streptococcal Skin Infection and a High Incidence of Invasive Infection. Infection and Immunity, 2004, 72, 364-370.	2.2	72

#	Article	IF	Citations
163	Fibronectin-Binding Protein Gene Recombination and Horizontal Transfer between Group A and G Streptococci. Journal of Clinical Microbiology, 2004, 42, 5357-5361.	3.9	33
164	Intranasal Vaccination with Streptococcal Fibronectin Binding Protein Sfb1 Fails To Prevent Growth and Dissemination of Streptococcus pyogenes in a Murine Skin Infection Model. Infection and Immunity, 2004, 72, 7342-7345.	2.2	35
165	Two Distinct Genotypes of prtF2, Encoding a Fibronectin Binding Protein, and Evolution of the Gene Family in Streptococcus pyogenes. Journal of Bacteriology, 2004, 186, 7601-7609.	2.2	34
166	An aromatic amino acid auxotrophic mutant ofBordetella bronchisepticais attenuated and immunogenic in a mouse model of infection. FEMS Microbiology Letters, 2003, 221, 7-16.	1.8	23
167	The pyruvate dehydrogenase complex of Mycoplasma hyopneumoniae contains a novel lipoyl domain arrangement. Gene, 2003, 319, 99-106.	2.2	18
168	Distribution of Intimin Subtypes among Escherichia coli Isolates from Ruminant and Human Sources. Journal of Clinical Microbiology, 2003, 41, 5022-5032.	3.9	131
169	stx 1c Is the Most Common Shiga Toxin 1 Subtype among Shiga Toxin-Producing Escherichia coli Isolates from Sheep but Not among Isolates from Cattle. Journal of Clinical Microbiology, 2003, 41, 926-936.	3.9	96
170	Evolution of sfbI Encoding Streptococcal Fibronectin-Binding Protein I: Horizontal Genetic Transfer and Gene Mosaic Structure. Journal of Clinical Microbiology, 2003, 41, 5398-5406.	3.9	31
171	Bovine Non-O157 Shiga Toxin 2-Containing Escherichia coli Isolates Commonly Possess stx 2-EDL933 and/or stx 2vhb Subtypes. Journal of Clinical Microbiology, 2003, 41, 2716-2722.	3.9	63
172	Asp274 and His346 Are Essential for Heme Binding and Catalytic Function of Human Indoleamine 2,3-Dioxygenase. Journal of Biological Chemistry, 2003, 278, 29525-29531.	3.4	66
173	Molecular Analysis of Group B Protective Surface Protein, a New Cell Surface Protective Antigen of Group B Streptococci. Infection and Immunity, 2002, 70, 803-811.	2.2	31
174	Streptococcus pyogenes prtFII, but not sfbI, sfbII or fbp54, is represented more frequently among invasive-disease isolates of tropical Australia. Epidemiology and Infection, 2002, 128, 391-396.	2.1	35
175	Production of truncated enzymically active human indoleamine 2,3-dioxygenase using site-directed mutagenesis. International Congress Series, 2002, 1233, 157-160.	0.2	0
176	Immunological response mounted by Aboriginal Australians living in the Northern Territory of Australia against Streptococcus pyogenes serum opacity factor The GenBank accession numbers for the sequences reported in this paper are AF367011 (sof VT3.2), AF367012 (sof VT3.1), AF367013 (sof VT2.2), AF367014 (sof VT21), AF367015 (sof VT37.1) and AF367016 (sof 13).. Microbiology (United Kingdom), 2002, 148, 169-178.	1.8	17
177	Oral immunization of swine with attenuated Salmonella typhimurium aro A SL3261 expressing a recombinant antigen of Mycoplasma hyopneumoniae (NrdF) primes the immune system for a NrdF specific secretory IgA response in the lungs. Microbial Pathogenesis, 2001, 30, 101-110.	2.9	30
178	The virulence factors ofBordetella pertussis: a matter of control. FEMS Microbiology Reviews, 2001, 25, 309-333.	8.6	76
179	The Common Ovine Shiga Toxin 2-Containing Escherichia coli Serotypes and Human Isolates of the Same Serotypes Possess a Stx2d Toxin Type. Journal of Clinical Microbiology, 2001, 39, 1932-1937.	3.9	68
180	Co-expression of theBordetella pertussisleader peptidase I results in enhanced processing and expression of the pertussis toxin S1 subunit inEscherichia coli. FEMS Microbiology Letters, 2000, 191, 177-182.	1.8	9

#	Article	IF	Citations
181	Role of Phosphoglucomutase of Bordetella bronchiseptica in Lipopolysaccharide Biosynthesis and Virulence. Infection and Immunity, 2000, 68, 4673-4680.	2.2	46
182	Expression and Purification of Recombinant Human Indoleamine 2,3-Dioxygenase. Protein Expression and Purification, 2000, 19, 22-29.	1.3	75
183	Expression of urease does not affect the ability of Bordetella bronchiseptica to colonise and persist in the murine respiratory tract. FEMS Microbiology Letters, 1999, 178, 7-11.	1.8	1
184	Contribution of adjuvant to adaptive immune responses in mice against Actinobacillus pleuropneumoniae. Microbiology (United Kingdom), 1999, 145, 2595-2603.	1.8	2
185	Characterisation of the urease gene cluster in Bordetella bronchiseptica. Gene, 1998, 208, 243-251.	2.2	40
186	Construction and characterisation of Salmonella typhimurium aroA simultaneously expressing the five pertussis toxin subunits. Vaccine, 1998, 16, 522-529.	3.8	14
187	Demonstration that Australian Pasteurella multocida isolates from sporadic outbreaks of porcine pneumonia are non-toxigenic (toxA-) and display heterogeneous DNA restriction endonuclease profiles compared with toxigenic isolates from herds with progressive atrophic rhinitis. Journal of Medical Microbiology, 1998, 47, 679-688.	1.8	26
188	Reiterated repeat region variability in the ciliary adhesin gene of Mycoplasma hyopneumoniae. Microbiology (United Kingdom), 1998, 144, 1931-1943.	1.8	55
189	A Second Two-Component Regulatory System of <i>Bordetella bronchiseptica</i> Required for Bacterial Resistance to Oxidative Stress, Production of Acid Phosphatase, and In Vivo Persistence. Infection and Immunity, 1998, 66, 4640-4650.	2.2	67
190	Temperature dependent expression of an acid phosphatase byBordetella bronchiseptica: role in intracellular survival. Microbial Pathogenesis, 1997, 22, 257-264.	2.9	26
191	Expression of a synthetic pertussis toxin operon in Escherichia coli. Vaccine, 1997, 15, 968-975.	3.8	3
192	Non-motile mini-transposon mutants of Bordetella bronchiseptica exhibit altered abilities to invade and survive in eukaryotic cells. FEMS Microbiology Letters, 1997, 146, 263-269.	1.8	1
193	Transfer of a pertussis toxin expression locus to isogenicbvg-positive andbvg-negative strains ofBordetella bronchisepticausing anin vivotechnique. Microbial Pathogenesis, 1996, 20, 263-273.	2.9	6
194	A novel Escherichia coli expression-export vector containing alkaline phosphatase as an insertional inactivation screening system. Gene, 1994, 148, 171-172.	2.2	14
195	Expression of Bordetella pertussis filamentous hemagglutinin in Escherichia coli using a two cistron system. Microbial Pathogenesis, 1992, 12, 383-389.	2.9	2
196	Engineering upstream transcriptional and translational signals of Bordetella pertussis serotype 2 fimbrial subunit protein for efficient expression in Escherichia coli: in vitro autoassembly of the expressed product into filamentous structures. Molecular Microbiology, 1990, 4, 39-47.	2.5	12
197	Construction of transposons encoding genes for Î²-glucosidase, amylase and polygalacturonatetrans-eliminase fromKlebsiella oxytoca and their expression in a range of gram-negative bacteria. Current Microbiology, 1988, 17, 69-75.	2.2	8
198	Cloning and characterization of an albicidin resistance gene from Klebsiella oxytoca. Molecular Microbiology, 1988, 2, 443-454.	2.5	47